Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, BlueGnome

Illumina this week launched its HumanCNV370-Duo, a microarray designed to specifically target novel regions of the genome that show copy number variation. The HumanCNV370-Duo was developed in collaboration with DeCode Genetics.
The HumanCNV370-Duo combines the content found on Illumina’s HumanHap300-Duo with an additional 55,000 markers specifically designed to target approximately 11,000 novel copy number variant regions, the firm said. In addition to providing coverage of SNPs from the International HapMap Project, the HumanCNV370-Duo also provides coverage for regions of the human genome believed to contain the majority of undiscovered CNVs.
Powered by Illumina's Infinium Assay, the HumanCNV370-Duo also enables researchers to analyze two samples simultaneously and access novel content for detecting disease-relevant CNV regions.
Content found on this BeadChip will also be available on Illumina's Human 1M BeadChip, a single-chip product that will profile over one million diverse genetic variants when it is released later this year, Illumina said.

BlueGnome said last week that its has validated its CytoChip version 1.1 bacterial artificial chromosome array against copy number variation data published by the Wellcome Trust Sanger Institute in the Nov. 26, 2006, issue of Nature [Redon, et al. Global variation in copy number in the human genome. Nature. 2006 Nov 23;444(7118):428-9].
According to BlueGnome, all 3,600 of the BAC clones on its CytoChip have been validated against the results published in Nature. The company said the validation will help minimize the risk of false positives in array comparative genomic hybridization studies that use its chip.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.